Works about GLUCAGON receptors
Results: 216
SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 6, p. 1091, doi. 10.1007/s10557-021-07243-6
- By:
- Publication type:
- Article
Tetrahydropalmatine from medicinal plants activates human glucokinase to regulate glucose homeostasis.
- Published in:
- Biotechnology & Applied Biochemistry, 2024, v. 71, n. 2, p. 295, doi. 10.1002/bab.2541
- By:
- Publication type:
- Article
Survodutide Improves MASH Without Worsening of Fibrosis in More Than 64% at 48 Weeks.
- Published in:
- Healio Gastroenterology, 2024, v. 10, n. 7, p. 38
- By:
- Publication type:
- Article
Oleanolic acid and moderate drinking increase the pancreatic GLP-1R expression of the β-cell mass deficiency induced hyperglycemia.
- Published in:
- PeerJ, 2023, p. 1, doi. 10.7717/peerj.15705
- By:
- Publication type:
- Article
Role of Glucagon and Its Receptor in the Pathogenesis of Diabetes.
- Published in:
- Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.928016
- By:
- Publication type:
- Article
Potential of a glucagon‐like peptide‐1 receptor/glucose‐dependent insulinotropic polypeptide receptor/glucagon receptor triagonist for the treatment of obesity and type 2 diabetes.
- Published in:
- Journal of Diabetes Investigation, 2022, v. 13, n. 12, p. 1958, doi. 10.1111/jdi.13896
- By:
- Publication type:
- Article
Combination SGLT2 Inhibitor and Glucagon Receptor Antagonist Therapy in Type 1 Diabetes: A Randomized Clinical Trial.
- Published in:
- Diabetes Care, 2025, v. 48, n. 1, p. 52, doi. 10.2337/dc24-0212
- By:
- Publication type:
- Article
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.
- Published in:
- Diabetes Care, 2024, v. 47, n. 11, p. 1873, doi. 10.2337/dci24-0003
- By:
- Publication type:
- Article
Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Antisense Inhibition of Glucagon Receptor by IONIS-GCGR<sub>Rx</sub> Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.
- Published in:
- Diabetes Care, 2016, v. 39, n. 11, p. e199, doi. 10.2337/dci16-0030
- By:
- Publication type:
- Article
Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.
- Published in:
- 2016
- By:
- Publication type:
- Opinion
Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Clinical Trials, Triumphs, and Tribulations of Glucagon Receptor Antagonists.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Evidence for a lack of inotropic and chronotropic effects of glucagon and glucagon receptors in the human heart.
- Published in:
- Cardiovascular Diabetology, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12933-023-01859-8
- By:
- Publication type:
- Article
Insights into the structure and activation mechanism of some class B1 GPCR family members.
- Published in:
- Molecular Biology Reports, 2024, v. 51, n. 1, p. 1, doi. 10.1007/s11033-024-09876-w
- By:
- Publication type:
- Article
γ-aminobutyric acid modulates α-cell hyperplasia but not β-cell regeneration induced by glucagon receptor antagonism in type 1 diabetic mice.
- Published in:
- Acta Diabetologica, 2023, v. 60, n. 1, p. 19, doi. 10.1007/s00592-022-01970-4
- By:
- Publication type:
- Article
Survodutide Wins FDA Breakthrough Therapy Designation for Noncirrhotic MASH Treatment in Adults.
- Published in:
- Patient Care (Online), 2024, p. 6
- By:
- Publication type:
- Article
Roche Oral Incretin Mimetic CT-966 Moves to Phase 2 Clinical Development.
- Published in:
- Patient Care (Online), 2024, p. 74
- By:
- Publication type:
- Article
Pemvidutide Preserves Lean Mass With Weight Loss of Nearly 16%: MOMENTUM Phase 2 Trial.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
The V369M Gcgr knock-in mice are a precision medicine model of mild Mahvash disease.
- Published in:
- Biochemical Journal, 2020, v. 477, n. 15, p. 2873, doi. 10.1042/BCJ20200522
- By:
- Publication type:
- Article
Characterization of a naturally occurring mutation V368M in the human glucagon receptor and its association with metabolic disorders.
- Published in:
- Biochemical Journal, 2020, v. 477, n. 13, p. 2581, doi. 10.1042/BCJ20200235
- By:
- Publication type:
- Article
Potential Therapeutic Targets in Obesity, Sleep Apnea, Diabetes, and Fatty Liver Disease.
- Published in:
- Journal of Clinical Medicine, 2024, v. 13, n. 8, p. 2231, doi. 10.3390/jcm13082231
- By:
- Publication type:
- Article
New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists.
- Published in:
- Biomedicines, 2024, v. 12, n. 6, p. 1320, doi. 10.3390/biomedicines12061320
- By:
- Publication type:
- Article
Insights into the Role of Glucagon Receptor Signaling in Metabolic Regulation from Pharmacological Inhibition and Tissue-Specific Knockout Models.
- Published in:
- Biomedicines, 2022, v. 10, n. 8, p. N.PAG, doi. 10.3390/biomedicines10081907
- By:
- Publication type:
- Article
Effects of insulin and the glucagon-like peptide 1 receptor agonist liraglutide on the kidney proteome in db/db mice.
- Published in:
- Physiological Reports, 2017, v. 5, n. 6, p. 1, doi. 10.14814/phy2.13187
- By:
- Publication type:
- Article
Peptide hormone sensors using human hormone receptor-carrying nanovesicles and graphene FETs.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-019-57339-1
- By:
- Publication type:
- Article
Assessment of glucagon receptor occupancy by Positron Emission Tomography in non-human primates.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41598-019-51530-0
- By:
- Publication type:
- Article
DR10627, a Novel Dual Glucagon‑like Peptide‑1 and Gastric Inhibitory Polypeptide Receptor Agonist for the Treatment of Obesity and Type 2 Diabetes Mellitus.
- Published in:
- Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy, 2024, v. 17, p. 1563, doi. 10.2147/DMSO.S457830
- By:
- Publication type:
- Article
12-Week Treatment with LY2409021 Significantly Lowers HbA1C and Is Well Tolerated in Patients with Type 2 Diabetes Mellitus.
- Published in:
- MD Conference Express, 2012, p. 16, doi. 10.1177/155989771216007
- By:
- Publication type:
- Article
Understanding Incretin Hormone Action and the Treatment of Diabetes.
- Published in:
- MD Conference Express, 2012, p. 6, doi. 10.1177/155989771216001
- By:
- Publication type:
- Article
Deleterious mutation V369M in the mouse GCGR gene causes abnormal plasma amino acid levels indicative of a possible liver-α-cell axis.
- Published in:
- Bioscience Reports, 2021, v. 41, n. 6, p. 1, doi. 10.1042/BSR20210758
- By:
- Publication type:
- Article
Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
- Published in:
- Canadian Journal of Physiology & Pharmacology, 2014, v. 92, n. 12, p. 975, doi. 10.1139/cjpp-2014-0310
- By:
- Publication type:
- Article
PYRAZOLE BEARING MOLECULES AS BIOACTIVE SCAFFOLDS: A REVIEW.
- Published in:
- Journal of the Chilean Chemical Society, 2020, v. 65, n. 1, p. 4746, doi. 10.4067/s0717-97072020000104746
- By:
- Publication type:
- Article
Structural signatures of the class III lasso peptide BI-32169 and the branched-cyclic topoisomers using trapped ion mobility spectrometry–mass spectrometry and tandem mass spectrometry.
- Published in:
- Analytical & Bioanalytical Chemistry, 2019, v. 411, n. 24, p. 6287, doi. 10.1007/s00216-019-01613-8
- By:
- Publication type:
- Article
hUCMSCs carrying exenatide prevent T1DM by improving intestinal microflora composition and islet tissue damage repair.
- Published in:
- Molecular Medicine, 2022, v. 28, n. 1, p. 1, doi. 10.1186/s10020-022-00526-0
- By:
- Publication type:
- Article
Structure of the human glucagon class B G-protein-coupled receptor.
- Published in:
- Nature, 2013, v. 499, n. 7459, p. 444, doi. 10.1038/nature12393
- By:
- Publication type:
- Article
GLP-1 Based Combination Therapy for Obesity and Diabetes.
- Published in:
- Journal of Obesity & Metabolic Syndrome, 2017, v. 26, n. 3, p. 155, doi. 10.7570/jomes.2017.26.3.155
- By:
- Publication type:
- Article
Decoding the Significance of Alpha Cell Function in the Pathophysiology of Type 1 Diabetes.
- Published in:
- Cells (2073-4409), 2024, v. 13, n. 22, p. 1914, doi. 10.3390/cells13221914
- By:
- Publication type:
- Article
Glucagon Promotes Gluconeogenesis through the GCGR/PKA/CREB/PGC-1α Pathway in Hepatocytes of the Japanese Flounder Paralichthys olivaceus.
- Published in:
- Cells (2073-4409), 2023, v. 12, n. 7, p. 1098, doi. 10.3390/cells12071098
- By:
- Publication type:
- Article
Glucagon Potentiates Insulin Secretion Via β-Cell GCGR at Physiological Concentrations of Glucose.
- Published in:
- Cells (2073-4409), 2021, v. 10, n. 9, p. 2495, doi. 10.3390/cells10092495
- By:
- Publication type:
- Article
Real-world effectiveness of GLP-1 receptor agonist-based treatment strategies on “time in range” in patients with type 2 diabetes.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1370594
- By:
- Publication type:
- Article
Survodutide, a glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo‐controlled, dose‐finding, phase 2 trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2025, v. 27, n. 2, p. 993, doi. 10.1111/dom.16052
- By:
- Publication type:
- Article
Cause‐specific death in adults with type 1 diabetes and type 2 diabetes: Insights from the UK Biobank.
- Published in:
- Diabetes, Obesity & Metabolism, 2025, v. 27, n. 1, p. 422, doi. 10.1111/dom.16009
- By:
- Publication type:
- Article
The efficacy and safety of ISIS 449884 injection as monotherapy in patients with type 2 diabetes: A randomized phase II study.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 11, p. 5466, doi. 10.1111/dom.15862
- By:
- Publication type:
- Article
Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 9, p. 3501, doi. 10.1111/dom.15693
- By:
- Publication type:
- Article
The dual GCGR/GLP‐1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 6, p. 2368, doi. 10.1111/dom.15551
- By:
- Publication type:
- Article
The role of glucagon‐like peptide‐1 receptor agonists in metabolic dysfunction‐associated steatohepatitis.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 6, p. 2001, doi. 10.1111/dom.15524
- By:
- Publication type:
- Article
Safety, pharmacokinetics and pharmacodynamics of HRS‐7535, a novel oral small molecule glucagon‐like peptide‐1 receptor agonist, in healthy participants: A phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose, and food effect trial
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 3, p. 901, doi. 10.1111/dom.15383
- By:
- Publication type:
- Article